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List of abbreviations and acronyms:  
ATRX: alpha-thalassemia mental retardation X-linked  
DAXX: death-domain associated protein 
HP1: heterochromatin protein 1 
OIS: oncogene-induced senescence 
PML: promyelocytic leukemia  
PML-NBs: PML nuclear bodies 
SAHF: senescence associated heterochromatin foci 
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Abstract 
Oncogene-induced senescence is a permanent cell cycle arrest characterized by extensive 
chromatin reorganization. Here, we investigated the specific targeting and dynamics of 
histone H3 variants in human primary senescent cells. We show that newly synthesized 
epitope-tagged H3.3 is incorporated in senescent cells but does not accumulate in senescence-
associated heterochromatin foci (SAHF). Instead, we observe that new H3.3 colocalizes with 
its specific histone chaperones within the promyelocytic leukemia nuclear bodies (PML-NBs) 
and is targeted to PML-NBs in a DAXX-dependent manner both in proliferating and 
senescent cells. We further show that overexpression of DAXX enhances targeting of H3.3 in 
large PML-NBs devoid of transcriptional activity and promotes the accumulation of HP1, 
independently of H3K9me3. Loss of H3.3 from pericentromeric heterochromatin upon 
DAXX or PML depletion suggests that the targeting of H3.3 to PML-NBs is implicated in 
pericentromeric heterochromatin organization. Together, our results underline the importance 
of the replication-independent chromatin assembly pathway for histone replacement in non-
dividing senescent cells and establish PML-NBs as important regulatory sites for the 
incorporation of new H3.3 into chromatin.  
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Introduction  
Most mammalian cells only divide for a limited number of times before they undergo 
terminal differentiation or enter the state of senescence. Cellular senescence may be triggered 
by various forms of stress stimuli. First described as the result of replicative exhaustion of 
cultured normal diploid cells 1, senescence can also be induced by oxidative stress, activated 
oncogenes such as H-RasV12 or inadequate growth conditions 2,3,4,5. Oncogene-induced 
senescence (OIS) results from a DNA damage response (DDR) activated by aberrant DNA 
replication 6,7,8 and may pose as an important anti-tumor barrier. Identification of senescent 
cells in benign or premalignant, but not malignant tissues or using various human and mouse 
model systems seems to support this hypothesis 9,10,11,12,13. Like terminal differentiation, 
senescence is characterized by irreversible cell cycle arrest and rigorous reorganization of 
cellular morphology, including the structure of the chromatin. 
Chromatin is comprised of nucleosomes that each consists of 147 base pairs of DNA wrapped 
around a core histone octamer. The histone octamer is composed of a central (H3-H4)2 
tetramer flanked by two H2A-H2B histone dimers 14. Three principle mechanisms bring about 
chromatin alterations in eukaryotic cells: i) post-translational modification of histone tails, ii) 
the action of chromatin remodeling enzymes and iii) the replacement of canonical histone 
proteins by histone variants 14. Incorporation of histone variants into chromatin is orchestrated 
by a family of proteins called histone chaperones 15 and may provide different biophysical 
properties to the chromatin fiber or different post-translational modification sites thus 
influencing nucleosome stability and function 14,16.  
Histone H3.3 is a variant of histone H3 that differs by only 5 amino acids from the canonical 
replicative histone variant H3.1 and has emerged as a regulator of chromatin states 17. H3.3 is 
constitutively expressed throughout the cell cycle and in quiescence 18 and is incorporated 
into chromatin in a DNA-synthesis-independent manner 19,20. It is enriched within actively 
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transcribed genes 21,22,23,24,25, but also accumulates at pericentromeric and telomeric 
heterochromatin regions 26,27,28. While the histone chaperone HIRA along with associated 
factors, ASF1a, Ubinuclein1 and Cabin1, is responsible for H3.3 deposition into active 
chromatin 19,20,27,29,30,31,32, the H3.3-specific chaperone DAXX in cooperation with the 
chromatin remodeler ATRX is essential for H3.3 deposition at heterochromatic loci 26,27,33. 
The ATRX/DAXX/H3.3 pathway has been implicated in the suppression of pancreatic 
neuroendocrine tumors (panNET) and paediatric glioblastomas 34,35,36,37,38,39 thus 
establishing its role in carcinogenesis. 
While establishment and maintenance of chromatin structure is central for genome function 40, 
how such a mechanism is achieved in senescent cells has remained unclear. Chromatin 
structure is extensively remodeled upon senescence entry as exemplified by the formation of 
senescence-associated heterochromatin foci (SAHF), visible as microscopically discernible, 
punctate DNA foci in DAPI-stained senescent cells 41. These structures are thought to 
contribute to the senescence-associated cell-cycle arrest in part by silencing proliferation-
promoting genes through heterochromatinization 41. Moreover, oncogene-induced SAHF 
formation may protect premalignant cells to undergo apoptosis by limiting extensive DNA 
damage to sub-lethal levels 42.  
Little is known about the underlying mechanisms of the extensive chromatin reorganization 
observed in senescent cells. SAHF are enriched in markers of heterochromatin including tri-
methylated histone H3 at lysine 9 (H3K9me3), all HP1 isoforms as well as HMGA proteins 
41,43. In addition, SAHF are also enriched in the histone H2A variant macroH2A 44, a variant 
associated with gene silencing as for example during X inactivation 45. Formation of 
MacroH2A- and HP1-containing SAHF is dependent on the two histone chaperones HIRA 
and ASF1a 44, suggesting that H3.3 may become enriched in SAHF during OIS 44,46. 
Interestingly, SAHF formation also depends on the prior localization of HIRA into 
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promyelocytic leukemia (PML) nuclear bodies (PML-NBs) 44,47, descrete foci, 0.2-1.0µm 
wide, that are present in most mammalian cell nuclei and stain positive for the tumor 
suppressor PML 48,49. PML-NBs have previously been implicated in the onset of OIS: they 
increase in number and size upon overexpression of H-RasV12 and overexpression of PML 
triggers p53-dependent senescence 50,51. Thus, PML-NBs may represent important regulatory 
structures not only for the induction of OIS in general but also for the establishment and 
maintenance of the specialized chromatin structure characteristic of the senescent state. 
In this study we set out to investigate the dynamics of H3.3 incorporation in senescent cells, 
and in particular its possible connection with PML-NBs. To this end we employed the novel 
SNAP-tagging approach, which has been successfully used to investigate the deposition of 
newly synthesized H3 variants in human cells 20,52. Surprisingly, we show here that H3.3 is 
not enriched in SAHF. Instead, we find that H3.3 is incorporated in active chromatin regions 
during senescence. In addition, we also observe the DAXX-dependent recruitment of H3.3 
into PML-NBs both in proliferating and senescent cells, thus establishing PML-NBs as 
important assembly points for newly synthesized H3.3 histones. We further show a decrease 
in the localization of H3.3 to satellite DNA regions upon depletion of DAXX or PML in 
human primary cells, thus linking the targeting of H3.3 to PML-NBs with the maintenance of 
pericentromeric heterochromatin.  
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Results 
An in vivo visualisation assay for newly synthesized H3.1 and H3.3 deposition in primary 
cells 
In order to address the dynamics of the histone variants H3.1 and H3.3 in proliferating and 
senescent cells, we established human MRC5 primary diploid fibroblasts stably expressing 
H3.1 or H3.3 tagged with SNAP and three HA epitopes (MRC5 e-H3.1 and e-H3.3, 
respectively). SNAP is a modified variant of a suicide DNA repair enzyme that catalyzes its 
own irreversible covalent binding to the cell-permeable molecule benzylguanine (BG). For in 
vivo labeling assays BG is replaced by fluorescent or non-fluorescent derivatives 53,54. This 
technique is tailor-made to visualize proteins synthesized at different time points, thus 
permitting to distinguish between old histone proteins and newly synthesized ones 20,52,54 
(Suppl. Fig. S1A). In particular, this system prooved essential to address the incorporation 
and localization of new histones in senescent cells, because in regular epitope-tagged H3 
expressing cell lines, it would be impossible to distinguish between incorporation of new 
histones versus chromatin-wide incorporation of H3 after senescence induction. 
We first verified by immunofluorescent staining that the tagged histones colocalize with 
mitotic chromosomes, indicating that the presence of the epitope tag does not interfere with 
the deposition of H3.1 nor H3.3 into chromatin in vivo (Suppl. Fig. S1B). We then validated 
in both cell lines the efficiency of our in vivo deposition assay based on quench-chase-pulse 
(QCP) labeling. Microscopic analysis shows that the pulse with TMR-Star labeled both pre-
existing H3.1 and H3.3 efficiently. In contrast, although pre-existing histones could still be 
labeled with HA antibody, a quench-pulse assay only gave background staining confirming 
the efficiency of quenching. A chase period during which new histone biosynthesis takes 
place then allowed the selective labelling of the new histones with TMR-Star (Fig. 1A and 
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Suppl. Fig. S1A-C). Furthermore, by combining quench-chase-pulse labeling assay with 
BrdU incorporation to detect replicating cells we confirmed that H3.1 deposition is limited to 
S-phase while H3.3 deposition occurs throughout the cell cycle (Suppl. Fig. S1B-D) 20. We 
conclude that human primary MRC5 cell lines expressing SNAP-HAx3-tagged histones are a 
powerful tool to analyse the mechanisms of de novo deposition of H3.1 and H3.3 at the 
single-cell level.  
 
Newly synthesized H3.3 is actively deposited in senescent cells while H3.1 is not 
To analyse the deposition of H3.1 and H3.3 variants in senescent cells, we induced 
senescence in MRC5 human primary diploid cells by overexpression of oncogenic Ras using 
retroviral-mediated gene transfer. At 8 days post-infection, MRC5 cells had arrested at sub-
confluent density, displayed reduced BrdU incorporation and showed the characteristic 
formation of SAHF visible as DAPI-dense foci, as described previously (Suppl. Fig. S2A,C) 
4,41. In addition, MRC5 cells also stained positive for the senescence-associated β-
galactosidase 55,56 thus confirming the entry into senescence (Suppl. Fig. S2B-C). We then 
overexpressed oncogenic Ras to induce senescence in MRC5 e-H3.1 or e-H3.3 cells (Fig. 1B) 
and performed quench-chase-pulse experiments to followed new histone deposition into 
chromatin. We verified that the newly synthesized histones are incorporated into chromatin 
by performing a detergent extraction to remove soluble histones prior to fixation of the cells 
(Suppl. Fig. S2D). Newly deposited H3.1 was detected in about 24% of proliferating cells 
(Fig. 1C-D), corresponding to S-phase cells (Suppl. Fig. S1C-D), consistent with previous 
work 19,20. In contrast, new H3.1 was not incorporated in senescent cells even though we 
could still detect the pool of pre-existing histones H3.1 by HA staining (Fig. 1C). 
Interestingly, pre-existing e-H3.1 accumulated at SAHF regions, marked as H3K9me3/ 
DAPI-dense foci, possibly as a result of the high condensation of these heterochromatin 
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regions (Fig. 2A-B). We next examined the deposition of new H3.3 in proliferating primary 
cells and confirmed its incorporation throughout the cell cycle in about 85% of cells. This 
number did not reach 100% because a certain percentage of cells expressed very low levels of 
recombinant histones, which resulted in undetectable TMR-star signal. Importantly, we could 
show for the first time de novo deposition of new H3.3 in senescent cells (Fig. 1C-D). 
Quantification of the number of TMR positive cells in Ras-arrested cells revealed that almost 
all senescent cells incorporated new H3.3 (Fig. 1D). Of note, endogenous H3.3 is still 
efficiently expressed in senescent cells (at about 60% of its levels in proliferating cells) as 
seen by quantitative PCR, as compared to a reduction to about 35% for H3.1 (Suppl. Fig. 
S3A-B) underscoring the importance to maintain a pool of H3.3 histones during senescence. 
Thus, our results suggest that replication-independent nucleosome assembly is the 
predominant mode of histone replacement in senescent cells.  
 
Newly synthesized H3.3 deposition in senescent cells correlates with active transcription 
We then decided to examine more closely where exactly newly synthesized H3.3 is deposited 
in senescent cells. Given the difficulty to specifically detect endogenous H3 variants by 
microscopy (H3.1 and H3.3 differ in only five amino acids), it has not yet been possible to 
determine the histone H3 variant composition of SAHF. These foci were originally described 
as transcriptionally inactive heterochromatin on the basis of the presence of all HP1 isoforms 
as well as H3K9me3 by immunofluorescence analysis 41,44. We first set out to confirm the 
transcriptionally silent state of SAHF. By combining immunostaining of H3K9me3 to detect 
SAHF with 5-Ethynyl uridine (EU) to label global nascent RNA transcription in vivo, we 
observed that EU labeling was clearly excluded from SAHF, marked as H3K9me3/ DAPI-
dense foci  (Fig. 2C). We quantified fluorescent intensity profiles along a line drawn through 
the centers of the nuclei of senescent cells and confirmed the inverse correlation between de 
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novo RNA synthesis and SAHF presence in MRC5 senescent cells (Fig. 2D). Thus, our 
results substantiate the transcriptionally silent state of the SAHF regions.  
Importantly, SAHF formation is in part regulated by the H3.3 histone chaperones HIRA and 
ASF1a 44,47, suggesting involvment of the H3.3 histone variant in this process. We thus 
investigated if new H3.3 becomes incorporated in SAHF by using our powerful in vivo 
deposition assay. We combined a quench-chase-pulse labelling of new H3.3 by TMR-star 
with H3K9me3 immunostaining as a marker of SAHF. We observed no enrichment of new 
H3.3 at H3K9me3/DAPI dense foci (Fig. 2E), confirmed by the striking reverse correlation of 
fluorescent intensity profiles of new H3.3 (TMR) and SAHF (H3K9me3 and DAPI-dense 
peaks) (Fig. 2F), reminiscent of the profiles observed with EU labelling. Confocal 
microscopy confirmed the absence of new H3.3 within SAHF in single plane images (Suppl. 
Fig. S3C) thus strongly indicating that most incorporation of new H3.3 in senescent cells 
takes place at transcriptionally active regions of the nucleus. While epitope-tagging can 
sometimes interfere with the function of the protein, we also extended these experiments to 
endogenous H3.3 by using a specific H3.3 antibody 26 for immunofluorescence analysis in 
IMR90 ER:Ras primary fibroblasts driven into senescence with addition of 4-
hydroxytamoxifen (4-OHT) 57 (Suppl. Fig. S3D). While the endogenous H3.3 behaved 
similarly to SNAP-HA-tagged recombinant H3.3, our data do not exclude the possibility that 
H3.3 could also be deposited in specific heterochromatic regions outside of SAHF.  
 
Newly synthesized H3.3 localizes in PML-NBs together with DAXX and ATRX in 
proliferating and senescent cells 
We next inspected more closely H3.3 labeling patterns in senescent cells. Remarkably, we 
noticed a distinct intranuclear focal H3.3 staining in the vast majority of cells, but not in 
MRC5 e-H3.1 cells, suggesting a distinct chromatin assembly pathway for H3.1 and H3.3. 
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Interestingly, the distinct nuclear H3.3 foci were also present in proliferating cells, although 
they were smaller in size and intensity as compared to senescent cells, reminiscent of the 
pattern observed for PML-NBs 50,51. We thus wondered if these H3.3 foci would co-localize 
with PML-NBs, together with its specific chaperones DAXX, ATRX, HIRA and ASF1a. 
Combined quench-chase-pulse labeling of new H3.3 by TMR-star with PML and 
DAXX/ATRX triple immunostaining clearly revealed that H3.3 co-localizes with PML-NBs 
in both proliferating and oncogene-induced senescent cells together with its associated histone 
chaperones DAXX and ATRX (Fig. 3A,C). We confirmed these data by fluorescent intensity 
profiles drawn through nuclei (Fig. 3B, D). We extended our results obtained on e-H3.3 to the 
endogenous histone H3.3 and showed its localization at PML-NBs both in proliferating and 
senescent human primary fibroblasts (Suppl. Fig. S4A). We also observed increased size and 
intensities of DAXX, ATRX, and new H3.3 foci in senescent cells (Figure 3 and Suppl. Fig. 
S4A) as demonstrated previously for PML-NBs 50,51. In addition, new H3.3 also co-localized 
with HIRA and ASF1a (Suppl. Fig. S4B).  
H3.3 interacts with DAXX and ATRX in proliferating cells 26,27,33. Hence, the strong co-
localization of e-H3.3 with DAXX and ATRX in PML-NBs in senescent cells prompted us to 
analyse the interaction of H3.3 with its chaperones in senescent cells. We first confirmed by 
western blot analysis of fractionated cell extracts that H3.3 as well as all H3.3 chaperones 
remain expressed in senescent MRC5 cells (Suppl. Fig. S3B), in contrast to the proliferative 
marker MCM7 or to the H3.1 histone chaperone CAF-1 58. We then purified histone 
complexes by HA immunoprecipitation in nuclear extracts from senescent MRC5 e-H3.1- and 
e-H3.3- expressing cells lines. Immunoblotting analysis of the purified complexes revealed 
the specific presence of DAXX and ATRX in H3.3 complexes but not of H3.1 in senescent 
cells (Fig. 3E) thus corroborating their function in H3.3 dynamics during senescence.  
Interestingly, before the function of DAXX and ATRX in histone H3.3 chromatin assembly 
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was identified, both factors were known to be components of PML-NBs in proliferating cells 
59,60 raising the possibility that these chaperones could localize in PML-NBs during 
senescence to regulate replication-independent chromatin assembly. We thus sought to verify 
the localization of these H3.3 chaperones as well as HIRA and ASF1a in PML-NBs in 
absence of H3.3 overexpression. While only a subpopulation of cells showed HIRA and 
ASF1a at PML-NBs in proliferating cells, this number increased upon senescence, as 
described previously 44,61. In contrast, ATRX and DAXX co-localized each in PML-NBs in 
almost all proliferating and senescent cells (Suppl. Fig. S4C). In addition, focal staining of all 
histone chaperones showed an increase in size and intensity in senescent cells, consistent with 
the pattern observed for PML-NBs 50,51. Of note, ATRX also localized to a fraction of SAHF 
in senescent cells, in addition to its localization to PML-NBs (Suppl. Fig. S4C and S9H). 
Together, our results indicate that new H3.3 localizes to PML-NBs together with its 
associated chaperones, and that this occurs in an increased manner during senescence.  
 
DAXX-dependent recruitment of H3.3 to PML-NBs 
We next made use of our in vivo deposition assay to directly assess the role of histone 
chaperones in targeting of H3.3 to PML-NBs both in proliferating and senescent cells. Co-
localization of DAXX and ATRX with new H3.3 at PML-NBs and their interaction with H3.3 
in both proliferating and senescent cells (Fig. 3) suggested that either chaperone could 
mediate H3.3 targeting to PML-NBs. To test this, we depleted DAXX and ATRX by RNA 
interference in MRC5 cells and first checked the efficiency of the knockdown by western blot 
analysis and ensured that depletion of each chaperone does not affect levels of the other 
(Suppl. Fig. S5A). Strikingly, specific depletion of DAXX with two different siRNAs, but 
not of HIRA nor H3.3, led to a dramatic loss of ATRX from the PML-NBs (Suppl. Fig. S5B) 
60 and was accompanied by a striking increase of ATRX localization at SAHF in Ras-induced 
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cells (Suppl. Fig. S6A-B). In contrast, downregulation of ATRX, HIRA or H3.3 did not 
affect DAXX localization in PML-NBs (Suppl. Fig. S5B). Thus, ATRX localization in PML-
NBs is DAXX-dependent.  
We then assessed the localization of newly synthesized H3.3 in PML-NBs in absence of 
DAXX or ATRX. To this end we first transduced MRC5 cells expressing e-H3.3 with empty 
vector or oncogenic Ras-expressing viruses followed by DAXX or ATRX depletion (Fig. 4A). 
Efficient downregulation of the H3.3 chaperones and expression of oncogenic Ras were 
verified by western blot analysis (Fig. 4B). We observed a dramatic loss of new H3.3 histones 
at PML-NBs upon DAXX depletion with two different sets of siRNAs, both in proliferating 
and in senescent cells (Fig. 4C), confirmed by quantification (Fig. 4D). As a control, PML 
depletion also led to a loss of H3.3 at PML-NBs (Suppl. Fig. S7A-C). In contrast, neither 
knockdown of ATRX (Fig. 4C-D) nor HIRA (Suppl. Fig. S7D-F) affected H3.3 localization 
at PML-NBs. Thus, our results reveal that DAXX promotes H3.3 recruitment to PML-NBs in 
proliferating and senescent cells.  
Given the essential role of PML in the induction of senescence through p53 activation and 
regulation of SAHF formation 44,50,51, we wondered if DAXX, ATRX or H3.3 depletion 
would impair Ras-induced senescence. We used two strategies to deplete DAXX and ATRX 
by shRNA. We either cotransduced MRC5 human primary fibroblasts with viruses encoding 
oncogenic Ras and the specific shRNA or we used IMR90 ER:Ras transduced with shRNAs 5 
days before induction of senescence by addition of 4-OHT. In both cases, we could not detect 
any defects in SAHF formation or senescence entry (Suppl. Fig. S8A-C and Suppl. Fig. 
S9A-E). Of note, overexpression of DAXX did not affect oncogene-induced senescence 
either because we observed normal reduction in Cyclin A levels, increase in p16 expression 
and normal SAHF formation in MRC5 and IMR90 ER:Ras overexpressing DAXX and the 
oncogenic form of Ras (Suppl. Fig. S8D-E and Suppl. Fig. S9E). In addition, we also 
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depleted DAXX, ATRX and H3.3 by siRNA in IMR90 ER:Ras one day before the induction 
of senescence. After 6 days of 4-OHT and 2 rounds of siRNA transfection to ensure 
continuous knock-down of the proteins, we could not detect any defects in senescence entry 
in DAXX- ATRX- and H3.3-depleted cells (Suppl. Fig. S9F-H). Thus, we decided to pursue 
our analysis in proliferating cells in order to investigate further the possible functions of H3.3 
localization in PML-NBs.  
 
DAXX overexpression increases localization of H3.3 at PML-NBs 
We first asked if overexpression of DAXX protein would trigger the reverse phenotype as 
observed upon DAXX depletion. We therefore transduced MRC5 e-H3.3 cells with 
retroviruses encoding Myc-DAXX. Upon overexpression of DAXX, triple immunostaining 
analysis showed perfect colocalization of new H3.3 with Myc-DAXX in PML-NBs along 
with a marked increase of the H3.3 signal within PML-NBs (Fig. 5A-B), sometimes leading 
to a massive accumulation of new H3.3 in a very large single PML-NB surrounded by a thin 
spherical enrichment of PML and DAXX proteins (Suppl. Fig. S10A). We then assessed if 
overexpression of recombinant DAXX could rescue the loss of H3.3 at PML-NBs in 
proliferating cells that were depleted from endogenous DAXX. To this end, we generated a 
siRNA-resistant derivative of Myc-DAXX by inserting silent mutations in the siRNA-target 
region and verified that it is not targeted by the siDAXX1 (Fig. 5B). Quench-chase-pulse 
labelling assays in MRC5 e-H3.3 cells depleted of endogenous DAXX showed that 
overexpression of Myc-DAXX rescues the localization of H3.3 in PML-NBs (Fig. 5C-D) and 
even leads to an increased H3.3 recruitment to PML-NBs, similar to the results obtained after 
overexpression of DAXX (Fig. 5A). Together, our results underline the essential role of 
DAXX for the recruitment of H3.3 to PML-NBs and rule out an off-target effect of our 
DAXX siRNA.  
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PML-NBs are not sites of H3.3 deposition but rather serve as interstages in the 
chromatin assembly pathway of H3.3 
While the precise roles of PML-NBs remains elusive, it was proposed that PML-NBs may 
serve as sites of storage for proteins or could be active sites for transcriptional and chromatin 
regulation 48. Importantly, in our analysis we observed that both the pools of soluble (Fig. 
3A-D) and incorporated new H3.3 (histones resistant to detergent extraction, Suppl. Fig. 
S10B) localize in PML-NBs, suggesting incorporation of H3.3 into chromatin within the 
PML-NBs. Given the non-random association of PML-NBs with transcriptionally active 
regions 62,63 and the importance of the histone variant H3.3 for transcriptional activation 17, 
we first tested if PML-NBs could be direct sites of H3.3 assembly during transcription. We 
took advantage of MRC5 cells overexpressing Myc-DAXX, which feature large PML-NBs 
(as observed in Fig. 5A) that contain DAXX and are surrounded by a thin PML “shell” (Fig. 
6A-B). We combined immunostaining of Myc and PML with 5-Ethynyl uridine (EU) to 
detect localization of the epitope-tagged DAXX proteins within the large PML-NBs and 
ongoing RNA transcription in vivo. We observed a striking exclusion of de novo RNA 
synthesis within the shell formed by PML proteins in the large PML-NBs (Fig. 6C) 
suggesting that PML-NBs do not contain any detectable nascent RNA. Of note, we also 
noticed a low DAPI intensity at the place of the large PML-NBs (Fig. 6C-D, Suppl. Fig. 
S10A) suggesting absence or low DNA content in these structures, consistent with previous 
work 64. In addition, we observed that new H3.3 still localizes to PML-NBs upon 
transcription inhibition with Actinomycin D in proliferating and senescent cells (Suppl. Fig. 
S11A-B). Thus, PML-NBs are unlikely to be direct sites of chromatin incorporation for H3.3 
and may rather function as storage bodies or indirectly regulate chromatin assembly pathways. 
Given the physical association of H3.3 with several histone chaperones within PML-NBs (Fig. 
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3, Suppl. Fig. S4B), we hypothesized that PML-NBs could be gathering points in the 
replication-independent chromatin assembly pathway for H3.3 before its deposition in 
specific genomic locations.  
 
H3.3 is targeted to pericentromeric heterochromatin in a DAXX- and PML-dependent 
manner 
To test this hypothesis, we focused on pericentromeric heterochromatin, a typical form of 
constitutive heterochromatin that is crucial for proper chromosome segregation. It is 
composed of DNA satellite repeats packed in heterochromatin that is associated with specific 
histone modifications such as H3K9me3 and is enriched in HP1 proteins 65. Interestingly, 
H3.3 was recently shown to be enriched in pericentromeric heterochromatin in mouse cells 26 
as well as in human cells 66. We first asked if PML-NBs contain pericentromeric 
heterochromatin markers. Thus, we performed immunofluorescence staining against HP1γ or 
H3K9me3 in MRC5 cells overexpressing Myc-DAXX. We observed a striking accumulation 
of HP1γ in the core of the large PML-NBs, but no local increase in H3K9me3 modification 
(Fig. 6D-E), suggesting the presence of a soluble pool of HP1 proteins within the PML-NBs. 
Of note, concentration of HP1γ into the large prominent nuclear body was not dependent on 
transcription or on any RNA component as it persisted in cells treated with Actinomycin D 
and RNaseA, respectively (data not shown).  
We then used chromatin immunoprecipitation (ChIP) to assess the localization of H3.3 
histones in our human primary MRC5 e-H3.3 stable cell lines. In normal MRC5 e-H3.3 cells, 
H3.3 localizes to the promoter of the active house-keeping gene GAPDH, as well as to 
centromeric (α-Satellite) and pericentromeric heterochromatin regions (Satellite III) (Fig. 7A). 
Upon depletion of DAXX by siRNA transfection (Fig. 7C), we observed a slight reduction of 
H3.3 localization at α-satellite regions and a much more prononced reduction at 
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pericentromeric heterochromatin (about 50% reduction) (Fig. 7A), whereas H3.3 localization 
at the GAPDH promoter was unaffected (Fig. 7B). Importantly, and in contrast to DAXX 
depletion, depletion of PML led to a marked decrease in the localization of H3.3 at both 
centromeric and pericentromeric heterochromatin (Fig. 7A), and also at the GAPDH promoter 
(Fig. 7B). These results suggest that depletion of PML (and disruption of PML-NBs) impairs 
H3.3 deposition at specific genomic locations both in euchromatin and heterochromatin. We 
next asked if DAXX-mediated targeting of H3.3 to pericentromeric heterochromatin via the 
PML-NB route would affect the levels of transcription of this region. To this end, we 
measured the levels of RNA transcripts for the satellite III region by qRT-PCR. In normal 
MRC5 cells, the level of Satellite III transcripts was below the detection limit, thus preventing 
us from studying a possible decrease in transcription upon DAXX knock-down. However, 
upon DAXX overexpression, we observed increased levels of Satellite III transcripts as 
measured by quantitative RT-PCR (Fig. 7D). We thus wondered if this increase was 
associated with an enhanced localization of H3.3 at the satellite III region. We performed 
ChIP against H3.3 histones in MRC5 e-H3.3 cells overexpressing Myc-DAXX. In 
comparison with empty MRC5 e-H3.3 cells, H3.3 localization to α-satellite regions was 
slighly increased, and a pronounced increase was observed at pericentromeric 
heterochromatin upon DAXX overexpression (Fig. 7E). H3.3 localization at the GAPDH 
promoter remained unaltered (Fig. 7F). Together, our results implicate PML-NBs in the 
histone H3.3 assembly process and support a model in which PML-NBs may play an 
important role for chromatin organization at specific genomic locations such as 
pericentromeric heterochromatin.      
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Discussion 
Our comprehensive analysis of H3.1 and H3.3 deposition in vivo provides novel insights into 
the dynamics of these H3 variants and their chromatin-assembly pathways in proliferating and 
senescent primary human cells. We show a global incorporation of new H3.3 in senescent 
cells with no accumulation into SAHF but instead localization in PML-NBs together with its 
known chaperones ASF1a, HIRA, DAXX and ATRX. We further demonstrate a specific role 
of DAXX in the targeting of H3.3 to PML-NBs in proliferating and senescent cells and we 
present evidence that this process is important for pericentromeric heterochromatin 
organization. Together, our results results implicate PML-NBs in the replication-independent 
chromatin assembly pathway of H3.3.  
 
Replication-independent chromatin assembly as a source of histone replacement in 
senescent cells  
While chromatin structure is inherently dynamic 67, the question of how chromatin is 
maintained in the absence of DNA replication has remained elusive. In particular, persistance 
of senescent melanocytes in benign human naevi in the human body for decades 9 highlights 
the need for chromatin maintenance mechanisms to secure the senescent phenotype. Whereas 
a global increase in protein content, as well as a specific increase in the macroH2A histone 
variant has been reported in senescence 44,68, a decrease in the protein levels of the histones 
H2A, H3 and H4 was described upon drug-evoked senescence or replicative aging 69,70 
suggesting that chromatin destabilization is associated with senescence. Here, we extend these 
results by reporting a dramatic decrease in H3.1 mRNA levels and a mild reduction of H3.3 
mRNA levels in OIS (Suppl. Fig. S3A). In addition, by taking advantage of the SNAP-
tagging technology to label new histones in human primary cells, we report that new H3.3 but 
not H3.1 is incorporated in senescent cells. While this result is not surprising given the 
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downregulation of the H3.1- specific histone chaperone CAF-1 in non-dividing cells 58,71, 
deposition of H3.3 in senescent cells suggests that replication-independent chromatin 
assembly is an important mode of histone replacement in non-dividing senescent cells. Recent 
studies identifying driver H3.3 mutations in pediatric glioblastomas 34,35,36,37, or linking H3.3 
incorporation with cellular memory 72, further underscore the physiological importance of 
H3.3 deposition for maintenance of chromatin structure and cell phenotype.  
 
H3.3 dynamics and SAHF formation 
Importantly, while formation of SAHF has been associated with the irreversibility of the cell 
cycle arrest 41,43,73, the molecular basis for their formation has remained elusive 74. SAHF 
formation is in part regulated by the H3.3 histone chaperones HIRA and ASF1a 44,47, 
suggesting involvement of the H3.3 histone variant in this process. Here we show that H3.3 
does not localize to SAHF during senescence, but is actually excluded from them (Fig. 2B 
and Suppl. Fig. S3C-D). Rather, H3.3 is found in transcriptionally active regions in 
senescent cells, consistent with previous data collected in proliferating cells that showed that 
H3.3 marks actively transcribed genes 21,22,23,24,25 and is enriched in post-translational 
modifications associated with the active chromatin state 75,76. In addition, we did not observe 
any defects in SAHF formation upon depletion of H3.3 or its chaperones ATRX and DAXX 
(Suppl. Fig. S8 and S9), suggesting that these proteins are not required for SAHF formation. 
This is consistent with recent data showing that SAHF are rather formed through the spatial 
rearrangement of pre-existing heterochromatin 77. However, absence of H3.3 from SAHF 
does not preclude its incorporation in other heterochromatic regions such as pericentromeric 
and telomeric heterochromatin regions (Fig. 7), which localize outside of SAHF 41,42,43,78. Of 
note, SAHF are dispensable for cellular senescence and mostly form in response to activated 
H-Ras in various cell types 79. Thus, deposition of H3.3, which is not linked to SAHF 
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formation, might also be an important process for chromatin maintenance in other types of 
senescence such as replicative senescence, or drug-induced senescence. Interestingly, we 
observed an enrichment of pre-existing H3.1 at SAHF (Fig. 1C and 2A-B), suggesting that 
the presence of H3.1 in SAHF may reflect a spatial repositionning of this variant within the 
H3K9me3-rich core region of SAHF 77, which would be consistent with patterns of repressive 
post-translational modifications (PTMs) found on H3.1 75,80. 
 
PML-NBs are novel regulatory sites for H3.3 replication-independent chromatin 
assembly  
While PML-NBs may have specific functions that are crucial for senescence entry 50,51,81, we 
show that H3.3 is found in PML-NBs in senescent but also in proliferating cells highlighting a 
novel role for these nuclear bodies as regulatory sites for H3.3 chromatin assembly pathways. 
We demonstrate that H3.3 localization to PML-NBs is dependent on DAXX, both in 
proliferating cells (consistent with data obtained in mouse ES cells 26), and in senescent cells. 
The structure of DAXX in complex with a dimer of H3.3-H4 82,83 suggests that H3.3 may be 
deposited onto PML-NBs as H3.3-H4 dimers. Indeed, a recent study by Delbarre et al. 
presents experimental evidence for this 84. In this work, DAXX- dependent H3.3 deposition in 
PML-NBs was also observed by using transient transfection of epitope-tagged H3.3 in slow 
growing human cells 84. Using the SNAP technology, we extend these findings to fast 
proliferating and senescent cells, indicating that localization to PML-NBs may be a universal 
replication-independent process of H3.3 targeting to chromatin that operates at all times, 
maybe also in terminally differentiated cells. 
Importantly, while H3.3 is found in complex with the other H3.3 chaperones 26,27,33 (Fig. 3E), 
its targeting to PML-NBs does not depend on ATRX and HIRA. For ATRX, a possible 
explanation is that interaction between ATRX and H3.3 may not be direct, but rather be 
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mediated by DAXX 26. In addition, recruitment of ATRX to PML-NBs is DAXX-dependent 
(Suppl. Fig. S5B and S6) 60 while the reverse is not true (Suppl. Fig. S5B). Thus, DAXX 
seems to be the key factor for the recruitment of ATRX and H3.3 to PML-NBs. Interestingly, 
our analysis performed in senescent cells revealed that ATRX localizes to SAHF in an 
increased manner when it is no longer targeted to PML-NBs upon DAXX depletion (Suppl. 
Fig. S6). While localization of ATRX at SAHF may be mediated through an interaction with 
H3K9me3 and HP1α 85,86, it remains to be determined whether this would have an impact on 
the chromatin dynamics of the macroH2A variant 87.  
Concerning HIRA and its associated chaperone ASF1a, we hypothesize that their localization 
in PML-NBs together with H3.3 could be a primary event before targeting of H3.3 to active 
genes 20,27. Interestingly, PML-NBs associate non-randomly with genomic regions that are 
transcriptionally active and nascent RNA has been detected in close proximity to PML-NBs 
48,62,63,64,88, suggesting that PML-NBs could control transcriptional activities indirectly by 
participating in the replication-independent assembly of H3.3 (Fig. 7B-C). Of note however, 
H3.3 loss from PML-NBs upon DAXX depletion does not affect the global incorporation of 
new H3.3 (Fig. 4C and 20) making it unlikely that localization of H3.3 to PML-NBs is a way 
to target this histone variant genome-wide. This also potentially explains the absence of a 
phenotype for the loss of H3.3 from PML-NBs in regards to senescence (Suppl. Fig. S8 and 
S9). Thus, as suggested in Delbarre et al., PML-NBs may be a gathering point for new H3.3 
histones before their targeting to specific genomic locations. 
Here we present novel evidence to support this hypothesis. First, we show that large PML-
NBs are devoid of transcriptional activity (Fig. 6C) and do not contain large amounts of DNA 
64, indicating that PML-NBs are unlikely to be direct sites for incorporation of H3.3 into 
chromatin and may rather represent novel interstages in the replication-independent pathway. 
Second, we show that upon DAXX overexpression, formation of large PML-NBs is 
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associated with an accumulation of new H3.3 (Fig. 5A, Suppl. Fig. S10A) together with HP1 
proteins, independently of H3K9me3 (Fig. 6D-E), consistent with data obtained in ICF cells 
89. These observations strenghten the connection between PML-NBs and heterochromatin 
components 89,90,91 and support a role of these nuclear bodies in heterochromatin dynamics. 
We hypothesize that the pool of HP1 could serve for pericentromeric heterochromatin 
organization together with new H3.3. Whether satellite DNA would directly localize in large 
PML-NBs as observed in G2 phase in ICF cells 89 is currently not known and should be 
examined further. Third, we show that depletion of DAXX (which abolishes H3.3 localization 
in PML-NBs) as well as depletion of PML impairs localization of H3.3 at pericentromeric 
heterochromatin (Fig. 7A,C) and that overexpression of DAXX increases localization of H3.3 
at these regions (Fig. 7D), thus implicating PML-NBs in heterochromatin organization. 
Recent data obtained in mouse ES cells showed that PML depletion impairs chromatin 
structure at telomeres 92, further underscoring the importance of PML-NBs in 
heterochromatin maintenance. 
Interestingly, failure to organize PML-NBs has been associated with the malignant state of 
prostate cancer 93, and the ATRX-DAXX-H3.3 pathway is mutated in cancers 34,35,36,37,38,39. 
How these chromatin assembly pathways are interconnected remains to be investigated. In 
summary, our data reveal new elements of chromatin maintenance in proliferating and 
senescent cells and implicate the enigmatic PML-NBs structures in the replication-
independent chromatin assembly pathways.  
 
 
 23 
 
Materials and Methods 
 
Human cell lines and retroviruses 
Human MRC5 primary lung fibroblast (ATCC) and human HEK 293T embryonic kidney 
cells (Intercell, AG) were cultivated in DMEM medium (GIBCO, Life Technologies). Human 
IMR90 ER:Ras primary lung fibroblast (a kind gift of Dr. Narita) were cultivated in DMEM 
medium without phenol red (GIBCO, Life Technologies). 4-hydroxytamoxifen (4-OHT, 
SIGMA) was added at a concentration of 100nM for 6 days to induce senescence. All media 
contained 10% FCS (GIBCO, Life Technologies), 100 units/mL of penicillin, 100 µg/mL of 
streptomycin, and 25 µg/mL of Fungizone® (amphotericin B) (Anti-anti, GIBCO, Life 
Technologies). MRC5 cell lines stably expressing H3.1-SNAP-HAx3 (e-H3.1), H3.3-SNAP-
HAx3 (e-H3.3), Myc-hDAXX or oncogenic Ras (H-RasV12) were established by retroviral 
transduction 94. Briefly, pBABE plasmids encoding H3.1-SNAP-HAx3 or H3.3-SNAP-HAx3 
(gift from L. Jansen), pLNCX2, pLNCX2 encoding Myc-hDAXX (generated by standart 
molecular biology procedures), pBABE-puro, pBABE-hygro, pBABE-puro and pBABE-
hygro encoding oncogenic Ras 7, pSuper.retro empty or pSuper.retro shDAXX1 95 or 
shATRX1 96 were co-transfected with pCL-ampho plasmid 97 by the calcium phosphate 
method into HEK 293T cells to package retroviral particles 98. After 48h, supernatant 
containing replication-incompetent retroviruses was filtered and applied for 24h on the target 
MRC5 cells in a medium containing polybrene 8ug/mL (SIGMA) 94. Stable transfectants 
were selected with Blasticidin S (5µg/mL, SIGMA), puromycin (1µg/mL, SIGMA), 
hygromycin (150µg/mL, SIGMA) or neomycin (G418, 1mg/mL, Calbiochem, Millipore) for 
3 days and a polyclonal population of cells was used for all experiments. Eventhough levels 
of expression of H3-SNAP-HAx3 were heterogenous within the cell population, we verified 
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the global low expression levels of tagged H3.1 and H3.3 by western blot as compared to the 
endogenous counterparts. 
 
siRNAs, shRNAs and transfections  
MRC5 cells were transfected in an antibiotics-free medium for the indicated number of days 
with 40nM siRNA using Lipofectamine RNAiMax reagent (Invitrogen, Life Technologies) 
and Opti-MEM 1 medium (GIBCO, Life Technologies) according to manufacturer's 
instructions. We used the following siRNA sequences: siLuc (non-targeting siRNA against 
Luciferase): 5'-CGUACGCGGAAUACUUCGA; siDAXX1: 5'-
GGAGUUGGAUCUCUCAGAA 99; siDAXX2: 5'- CAGCCAAGCUCUAUGUCUA 20; 
siDAXX3: 5'- CAGAAACAUUAAUAAACAAUA 100; siATRX1: 5'-
GAGGAAACCUUCAAUUGUA 96; siATRX2: 5'- GCAGAGAAAUUCCUAAAGA 96; 
siH3.3A: 5'-CUACAAAAGCCGCUCGCAA 101; siH3.3B: 5'-
GCUAAGAGAGUCACCAUCA  101; siHIRA: 5'-GGAUAACACUGUCGUCAUC 20; 
siPML: 5'- GUGCUUCGAGGCACACCAG 102. We used siRNAs against H3.3A and H3.3B 
together, or ATRX1 and ATRX2 together, at a final concentration of 20nM each to achieve 
depletion of H3.3 and ATRX respectively. 
We used the following shRNA sequences cloned into a pSuper.retro vector: shDAXX1: same 
as siDAXX1 95, shATRX1: 5'-
GATCCCCGAGGAAACCTTCAATTGTATTCAAGAGATACAATTGAAGGTTTCCTCT
TTTTA 96. 
 
Antibodies 
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Supplementary Table SI compiles all primary antibodies used in this study. Company, as 
well as the order number, the lot number, the species and the dilutions for western blotting 
(WB) and immunofluorescence (IF) are provided for each antibody. 
 
H3-SNAP Labeling in vivo 
The SNAP-labeling protocol is as described in 52,54. 4µM of SNAP-Block (New England 
Biolabs) was added during 30 minutes at 37°C to the cell medium to quench the SNAP-tag 
activity or 2µM of SNAP-Cell TMR-Star (New England Biolabs) during 20 minutes for pulse 
labeling. After washing of cells with prewarmed PBS, reincubation in complete medium for 
30 min allowed excess compound to diffuse from cells and then cells were washed again in 
PBS. For the chase, incubation of cells was for 3 hours and 30 minutes in complete medium at 
37°C. Actinomycin D was added at a dose of 2µg/mL for the total lenght of the chase (3h30) 
to prevent transcription of new H3.3, or at the end of the chase (for 1h30) to allow synthesis 
of new H3.3 before transcription inhibition (see Suppl. Fig. S11). After in vivo labeling, the 
cells were processed for immunostaining.  
 
Immunofluorescence microscopy 
Cells grown on coverslips were directly fixed with 4% formaldehyde or pre-extracted with 
detergent prior to fixation. Indeed, to detect histones incorporated into chromatin only, 
soluble proteins were extracted for 2 minutes in cold CSK buffer (10 mM PIPES pH 7, 100 
mM NaCl, 300 mM sucrose, 3 mM MgCl2) containing 0.5% of Triton X-100 (SIGMA), and 
rinsed with CSK and PBS before fixation. For immunofluorescence, we permeabilized cells in 
PBS containing 0,2% Triton X-100. We then blocked cells with BSA (5% in PBS containing 
0.1% Tween 20) for 20 minutes before incubation with primary antibodies (Suppl. Table SI) 
for one hour, followed by washes in PBS 0.1% Tween, and then incubation with secondary 
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antibodies for 30 minutes. Cross-absorbed Alexa-488, Alexa-594 or Alexa-647 conjugated 
secondary antibodies (Invitrogen, Molecular probes) were used to detect primary antibodies. 
Coverslips were mounted in Vectashield (Vector Laboratories) containing DAPI. To label 
global nascent RNA transcription in vivo, we incubated cells with 5-Ethynyl uridine (EU, 
Invitrogen, Molecular probes), a nucleoside analog of uracil incorporated into RNA during 
active RNA synthesis, at 1mM for 3 hours. Nascent RNA was revealed with the Click-iT 
Chemistry (Alexa Fluor 594) according to the manufacturer instructions.  
 
Microscopy Analysis and Quantification of TMR Signal 
We acquired images with a DMI600B (Leica) inverted widefield epifluorescence microscope 
(63X objective/NA 1.32 or 40X objective/NA 1.0) piloted with Leica Application Suite 
(LAS) and equipped with a Leica DFC365 FX black & white camera or a Leica DFC 295 
color camera. We applied identical settings and the same contrast adjustment for all images to 
allow accurate data comparison, except on Fig. 4C where TMR signal was adjusted to a 
similar intensity in all conditions to compare localization of new H3.3 at PML-NBs. For 
brightness and contrast adjustment, we used Adobe Photoshop CS3 (Adobe) and Image J. 
To quantify fluorescence intensity (TMR signal) in the acquired images, we used the ImageJ 
software. Briefly, we defined borders of nuclei using HA immunostaining and we then 
quantified total gray value for TMR in each nucleus (integrated density). We set a threshold 
value above which cells were considered as positive for TMR staining and then calculated the 
number of TMR positive cells for each cell line. We used RGB profiler and interactive 3D 
surface plot plugins to quantify fluorescence intensity along a line drawn through the nucleus 
or within all nucleus respectively. A minimum of 100 nuclei was counted in each experiment. 
 
Western blotting  
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For total extracts, we lysed cells in Laemmli sample buffer (LSB) 1X (62,5mM Tris HCl 
pH=6.8, 10% glycerol, 2% SDS, 0.002% bromophenol blue and 100mM DTT). For whole 
cell extracts (Fig. 1B), after two washes in PBS, we lysed cells in lysis buffer (50mM Tris-
HCl, pH=7.5, 300mM NaCl, 1mM EDTA, 0.5% NP-40, 5% glycerol) containing protease 
inhibitors (10µg/mL leupeptin (SIGMA), 10µg/mL of pepstatin A (SIGMA), 100µM PMSF 
(SIGMA)) and phosphatase inhibitors (5mM sodium fluoride (SIGMA), 10mM β-
glycerophosphate (SIGMA), 0.2mM sodium orthovanadate (SIGMA)). We incubated lysates 
for 20 minutes on ice and then spinned them for 20 minutes at 14 000g. We kept the 
supernatant as whole cell extracts. For cellular fractionation (Fig. 3E, Suppl. Fig. S3B), we 
performed cytosolic and nuclear extracts as described in 80,103 with buffers containing 
protease and phosphatase inhibitors as described above. We loaded extracts on SDS-
polyacrylamide gels and performed electrophoresis. We used Ponceau 1% (SIGMA) to detect 
proteins transferred on nitrocellulose membranes. We used primary antibodies as described in 
Suppl. Table SI. We used secondary antibodies conjugated with Horseradish peroxidase 
(HRP) (GE Healthcare Life sciences) and revealed signal by chemiluminescence substrate 
from Amerscham (SuperSignal West Pico or SuperSignal West Femto) (GE Healthcare Life 
sciences).  
 
Immunoprecipitation 
For immunoprecipitation, we used 150µg of Nuclear extracts from plain MRC5, or MRC5 e-
H3.1 and MRC5 e-H3.3 transduced with pBABE-puro or pBABE-puro-H-RasV12 
retroviruses for 8 days. We performed the immunoprecipitation for 2 hours with HA beads 
(SIGMA A2095 clone HA-7) in IP buffer (20 mM Tris at pH 7.6, 150 mM NaCl, 3 mM 
MgCl2, 0.1 mM EDTA, 10% glycerol, 0.1% NP-40) containing protease and phosphatase 
inhibitors as described above. After 3 washes in IP buffer with a 5 minutes incubation at 4°C 
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for each wash, beads were resuspended in LSB 1X buffer and 100mM DTT, boiled 10 
minutes and the supernatant was then loaded on an SDS-polyacrylamide gel for further 
Western Blot analysis. 
 
Chromatin immunoprecipitation (ChIP) 
ChiP was performed as described in 104. Briefly, MRC5, MRC5 e-H3.1 or e-H3.3 cells, 
treated or not with siRNAs for 72 hours, or transduced with viruses encoding Myc-DAXX for 
overexpression of DAXX for 7 days, were crosslinked in 1% formaldehyde for 10 minutes at 
room temperature. After stopping the reaction with 0.125M of Glycine for 5 minutes at room 
temperature, cells were washed in PBS, scraped in a tube and lysed in 85mM KCl, 5mM 
PIPES pH=8.0, 1% NP-40 containing leupeptin (10mg/mL), pepstatin (10mg/mL) and PMSF 
(1mM) for 15 minutes on ice. Cells were homogenized using a glass dounce homogenizer and 
nuclei were released with 20 strokes on ice. After centrifugation, nuclei were subsequently 
lysed in nuclei lysis buffer containing 50 mM Tris–HCl pH=8.0, 10 mM EDTA, 1% SDS and 
protease inhibitors as described above. Sonication was performed using a Bioruptor 
(Diagenode) for 30 minutes with 30s ON-30s OFF pulses to achieve an average chromatin 
length of 200–500 bp. After centrifugation, chromatin from 4x10e6 cells was diluted 5 times 
in ChIP dilution buffer (50 mM Tris–HCl pH=7.4,150 mM NaCl, 1% NP-40, 0.25% sodium 
deoxycholic acid, 1mM EDTA pH=8.0 containing protease inhibitors as described above) and 
immunoprecipitated overnight at 4°C with 1µg of Rabbit IgG or HA antibody. Protein A 
agarose beads (Millipore #16-157) were added for 2 hours at 4°C. After extensive washes as 
described in 104, bound chromatin was eluted for 30 minutes in elution buffer (50mM 
NaHCO3, 1% SDS) and decrosslinked overnight at 67°C in the elution buffer containing 
0.54M NaCl. Samples from input chromatin (10%) were diluted 4 times in elution buffer 
containing 0.54M NaCl and decrosslinked as ChIP samples. After treatment of samples with 
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RNaseA for 20 minutes at 37°C, DNA was purified with PCR purification kit (QIAGEN). 
Quantitative PCR was performed as described in Supplementary Materials and methods.  
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Figure legends  
 
Figure 1: Dynamics of H3.1 and H3.3 deposition in proliferating and senescent human 
cells.  
A. Fluorescent microscopy visualization of H3.1- and H3.3-SNAP-HAx3 after in vivo 
labeling assays of MRC5 human primary cells with red fluorescent TMR-Star in pulse, 
quench-pulse, and quench-chase-pulse experiments. The pulse labels pre-existing H3-SNAP, 
the quench-pulse quenches pre-existing H3-SNAP with nonfluorescent block preventing their 
subsequent labeling with TMR-Star (background), and the quench-chase-pulse labels new 
H3-SNAP synthesized during the 3h30 chase. In all cases, HA stains total histone H3. DAPI 
stains nuclei. Scale bar is 10 µm. (See also Suppl. Fig. S1). 
B. Western blot analysis of whole cell extracts from MRC5 stably expressing H3.1- or H3.3 
SNAP-HAx3 (e-H3.1 and e-H3.3, respectively) and transduced with an empty retroviral 
vector (empty) or with a vector expressing H-RasV12 (Ras) for 10 days. 25µg of protein 
extracts were loaded. HA and Ras stainings verified expression of the transduced proteins. 
Mcm7 was used as a marker for cell proliferation and p16 as a marker for proliferation arrest. 
Smc-1 served as a loading control. M: molecular weight marker. (See also Suppl. Fig. S2A-
C).  
C. Fluorescent microscopy visualization of new H3.1 and H3.3 (TMR, red) after in vivo 
labelling of MRC5 e-H3.1 and e-H3.3 treated as in (B) in a quench-chase-pulse experiment. 
HA (green) stains total H3 histones and DAPI stains nuclei. Scale bar is 10 µm. (See also 
Suppl. Fig. S2D). 
D. Histogram shows quantitative analysis of the proportion of TMR positive cells in MRC5 e-
H3.1 or e-H3.3 proliferating (empty) and senescent (Ras) cells. Numbers represent the mean 
of 3 independent experiments ± s.d. 
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Figure 2: New H3.3 deposition does not occur into SAHF, in contrast to parental H3.1, 
but correlates with transcriptional activity in human senescent cells.  
A. Fluorescent microscopy visualization of pre-existing H3.1 (HA, green) in MRC5 e-H3.1 
cells proliferating (empty) or induced into senescence with H-RasV12 overexpression (Ras) 
for 8 days. H3K9me3 (red) and DAPI were used as markers for SAHF formation. Scale bar is 
10 µm.  
B. Graphics show fluorescent intensity profiles quantified by Image J along lines drawn 
through nuclei as shown in panel (A). 
C. Fluorescent microscopy visualization of nascent global RNA transcription in vivo in 
MRC5 cells treated as in (A). Nascent RNAs were labeled with 5-ethynyl uridine (EU) for 3 
hours and revealed by the Click-iT chemistry (red). H3K9me3 (green) and DAPI were used as 
markers for SAHF formation. Scale bar is 10 µm. 
D. Graphics show fluorescent intensity profiles quantified using Image J along lines drawn 
through nuclei as shown in panel (C). 
E. Fluorescent microscopy visualization of new H3.3 (TMR, red) after in vivo labelling of 
MRC5 e-H3.3 cells treated as in (A) in a quench-chase-pulse experiment. H3K9me3 (green) 
and DAPI were used as markers for SAHF formation. Scale bar is 10 µm. (See also Suppl. 
Fig. S3C-D). 
F. Graphics show fluorescent intensity profiles quantified by Image J along lines drawn 
through nuclei as shown in panel (E). 
 
Figure 3: New H3.3 localizes in PML-NBs together with DAXX and ATRX in 
proliferating and senescent cells. 
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A. Fluorescent microscopy visualization of new H3.3 (TMR, red) after in vivo labelling of 
proliferating (empty) or senescent (Ras) MRC5 e-H3.3 cells in a quench-chase-pulse 
experiment. Co-staining with DAXX (green) and PML (cyan, pseudo-color) shows 
colocalization of new H3.3 with its chaperone DAXX in PML-NBs. Merge images represent 
PML in blue, DAXX in green, and new H3.3 (TMR) in red. Scale bar is 10 µm. (See also 
Suppl. Fig. S4A-B). 
B. Graphics show fluorescent intensity profiles quantified using Image J along lines drawn 
through nuclei as shown in panel (A). 
C. Fluorescent microscopy visualization of new H3.3 (TMR, red) after in vivo labelling of 
MRC5 e-H3.3 cells treated as in (A) in a quench-chase-pulse experiment. Co-staining with 
ATRX (green) and PML (cyan, pseudo-color) shows colocalization of new H3.3 with its 
chaperone ATRX in PML-NBs. Merge images represent PML in blue, ATRX in green, and 
new H3.3 (TMR) in red. Scale bar is 10 µm. 
D. Graphics show fluorescent intensity profiles quantified by Image J along lines drawn 
through nuclei as shown in panel (C). 
E. Immunoprecipitation performed against HA tag on 150µg of nuclear cell extracts from 
regular MRC5 cells (negative control) or MRC5 e-H3.1 or e-H3.3. Cells were either 
proliferating (empty) or induced into senescence by overexpression H-RasV12 (Ras) for 8 
days. Input is 10% of the immunoprecipitated material. Membranes were probed for HA as a 
control for IP, for Mcm7 as a marker of cell proliferation and negative control for IP, and for 
DAXX and ATRX. M: molecular weight marker.  
 
Figure 4: New H3.3 is lost from PML-NBs in DAXX-depleted cells. 
A. Scheme for the assay of in vivo labeling of new H3.3 in MRC5 e-H3.3 induced into 
senescence and depleted of specific histone H3.3 chaperones.  
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B. Western blot analysis of total cell extracts from MRC5 e-H3.3 treated as in (A). 
Membranes were probed for HA and Ras to verify expression of the transduced proteins, and 
for DAXX and ATRX. Smc1 served as a loading control. M: molecular weight marker 
C. Fluorescent microscopy visualization of new H3.3 (TMR, red) after in vivo labelling of 
MRC5 e-H3.3 cells treated as in (A) in a quench-chase-pulse experiment. Co-staining with 
PML (green) shows loss of new H3.3 at PML-NBs upon DAXX depletion. Insets represent 
enlarged images (3X) of selected area. Scale bar is 10 µm. (See also Suppl. Fig. S7). 
D. Histogram shows quantitative analysis of the proportion of cells showing new H3.3 
localization at PML-NBs. Numbers represent the mean of 3 independent experiments ± s.d. 
 
Figure 5: Overexpression of DAXX increases new H3.3 localization at PML-NBs 
A. (Left panel) Fluorescent microscopy visualization of new H3.3 (TMR, red) after in vivo 
labeling of MRC5 e-H3.3 cells in a quench-chase-pulse experiment. MRC5 e-H3.3 cells 
transduced with an empty vector (Empty) or a vector expressing Myc-DAXX (Myc-DAXX) 
were co-stained with Myc (green) and PML (cyan, pseudo-color). Scale bar is 10 µm. (Right 
panel) Graphics show distribution of new H3.3 (TMR) signal in MRC5 e-H3.3. TMR 
fluorescence intensity of each pixel delimited within the nuclei is plotted in a 3D-surface plot 
and shows increase in the targeting of new H3.3 at PML-NBs upon DAXX overexpression. 
(See also Suppl. Fig. S10A).   
B. Western blot analysis of total cell extracts from MRC5 e-H3.3 treated as in (A) (left panel) 
or as in (C) (right panel). Membranes were probed for HA and Myc to verify expression of 
the transduced proteins, and for DAXX. α-Tubulin is a loading control. M: molecular weight 
marker. 
C. (Left panel) Fluorescent microscopy visualization of new H3.3 (TMR, red) after in vivo 
labeling of MRC5 e-H3.3 cells in a quench-chase-pulse experiment. Control MRC5 e-H3.3 
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cells and MRC5 e-H3.3 cells co-expressing a siRNA resistant form of Myc-DAXX were 
transfected for 2 days with the indicated siRNAs before labeling with TMR and co-staining 
with Myc (green) and DAXX (cyan, pseudo-color). Scale bar is 10 µm. (Right panel) 
Graphics showing distribution of new H3.3 (TMR) signal intensity as in (A), reveals rescue of 
new H3.3 localization to PML-NBs upon re-expression of DAXX. 
D. Histogram shows quantitative analysis of the proportion of cells showing new H3.3 
localization at PML-NBs. Numbers represent the mean of 2 independent experiments ± s.d. 
 
Figure 6: Overexpression of DAXX triggers formation of large PML-NBs together with 
an accumulation of HP1 proteins in these nuclear bodies. 
A. Western blot analysis of total cell extracts from MRC5 cells transduced with an empty 
vector or a vector expressing Myc-DAXX. Membranes were probed for Myc to verify 
expression of the transduced proteins, and for DAXX. α-Tubulin is a loading control. M: 
molecular weight marker. 
B. Fluorescent microscopy visualization of PML (green) and DAXX (red) in MRC5 cells 
treated as in (A) shows formation of large PML-NBs upon Myc-DAXX overexpression 
(white arrowheads). Scale bar is 10 µm.  
C. Fluorescent microscopy visualization of nascent global RNA transcription in vivo in 
MRC5 cells empty or overexpressing Myc-DAXX. Nascent RNAs were labeled with 5-
Ethynyl Uridine (EU) for 3 hours and revealed by the Click-iT chemistry (red). Co-staining 
with Myc (green) and PML (cyan, pseudo-color) shows absence of transcription within the 
large PML-NBs upon overexpression of DAXX. Insets represent enlarged images (3X) of 
selected area. Scale bar is 10 µm. 
D and E. Fluorescent microscopy visualization of Myc-DAXX (Myc, green) and HP1γ or 
H3K9me3 (red) in MRC5 cells treated as in (A) shows accumulation of HP1γ (D) in absence 
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of H3K9me3 (E) in the large PML-NBs upon overexpression of Myc-DAXX (white 
arrowheads). Scale bar is 10 µm.  
 
Figure 7: Enrichment of H3.3 in pericentromeric heterochromatin is dependent on 
DAXX and PML proteins 
A. Histogram shows analysis of H3.3 incorporation in centromeric (Satellite α) or 
pericentromeric heterochromatin (Satellite III) by ChIP against the HA epitope in MRC5 e-
H3.3 cells treated for 72h with the indicated siRNAs. QPCR data are presented as fold 
enrichment of IP over input DNA. MRC5 untransduced cells serve as a negative control. 
Numbers represent the mean of 2 independent experiments ± s.d.  
B. Histogram shows analysis of H3.3 incorporation at the GAPDH promoter region by ChIP 
assay performed as in (A). Numbers represent the mean of 2 independent experiments ± s.d. 
C. Western blot analysis of total cell extracts from MRC5 e-H3.3 cells treated as in (A). 
Membranes were probed for PML and DAXX to verify depletion of these proteins, and for 
HA to verify expression of the transduced proteins. α-Tubulin is a loading control. M: 
molecular weight marker.  
D. Satellite III mRNA expression levels in empty MRC5 cells or MRC5 cells overexpressing 
Myc-DAXX as determined by quantitative RT-PCR. mRNA levels were normalized to the 
reference gene GAPDH and levels were set to 100% in empty cells. Numbers represent the 
mean of 3 independent experiments ± s.d. 
E. Histogram shows analysis of H3.3 incorporation in centromeric (Satellite α) or 
pericentromeric heterochromatin (Satellite III) by ChIP against the HA epitope in MRC5 e-
H3.3 cells transduced with an empty vector (empty) or a vector encoding Myc-DAXX (Myc-
DAXX). QPCR data are presented as fold enrichment of IP over input DNA. IP with IgG 
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control antibody in MRC5 e-H3.3 cells serves as a negative control. Numbers represent the 
mean of 2 independent experiments ± s.d.  
F. Histogram shows analysis of H3.3 incorporation at the GAPDH promoter region by ChIP 
assay performed as in (E). Numbers represent the mean of 2 independent experiments ± s.d. 
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Supplementary Materials and Methods 
Immunofluorescence microscopy 
For senescence-associated Beta-Gal assay, we followed protocols published in 1,2. For 
detection of replicating cells 8 to 12 days after infection, we pulse-labeled cells in vivo with 
10µM of BrdU (SIGMA) for 2 hours (Fig. S2A). Alternatively, we pulse-labeled cells in vivo 
with 40µM of BrdU during the TMR-Star pulse labeling in the last 20 minutes (Fig. S1C). In 
order to detect BrdU, we denatured fixed cells for 10 minutes in 4N HCl, followed by 
extensive washes in PBS and we then detected BrdU by standard immunofluorescence as 
described in main text. 
 
Microscopy Analysis and Quantification of TMR Signal 
We carried out confocal microscopy with a Leica SP5 confocal laser scanning  
microscope (Leica, Heerbrugg, Switzerland) equipped with a  
Plan-Apochromat 63x NA 1.4 oil immersion objective (Fig. S3C). We acquired dual confocal 
images with standard settings using laser lines 488nm and 561nm for excitation of Alexa 
Fluor 488 and TMR-Star dyes respectively. We used band pass filters 498-552nm and 588-
647nm to collect the emitted fluorescence signals. We imaged nuclear DAPI using excitation 
by 405nm laser and band pass filter 410-452nm. Images from Fig. S3C represent single 
confocal planes. 
 
RNA extraction and Quantitative RT-PCR  
We used the RNeasy mini kit (QIAGEN) for total RNA extraction. After treating 1µg of RNA 
with Turbo DNAse (AMBION, Life Technologies) according to the manufacturer's 
instructions. We then performed reverse transcription using MMLV reverse transcriptase 
(Promega) with 100ng of random primers (ABI, Life Technologies) per reaction, respectively. 
 3 
For quantitative PCR analysis, we used the 96-well plate LightCycler 480 Real-time PCR 
system from Roche and the SYBR Green PCR Master mix (Roche). We checked the 
efficiency of each primer pair (sequences below) with four cDNA dilutions of a standart 
cDNA. We measured duplicates (ChIP) or triplicates (quantiative RT-PCR) in all experiments 
and we normalized the quantity of mRNA to the quantity of mRNA corresponding to the 
human Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). As a control when measuring 
SatIII RNA levels, all quantitative RT-PCRs were also performed in control samples lacking 
reverse transcriptase. Primer pairs for the quantitative RT-PCRs were the following: H3.1-F 
5'-GGTGCGAGAAATAGCTCAGG-3'; H3.1-R 5'- CAAAACAATTCACGCCCTCT-3'; 
H3.3A-F 5'- CCAGGAAGCAACTGGCTACA-3'; H3.3A-R 5'- 
ACCAGGCCTGTAACGATGAG-3'; H3.3B-F 5'- GGATTTCAAAACCGACCTGA-3'; 
H3.3B-R 5'-AGCCAACTGGATGTCTTTGG-3'; GAPDH-F 5'- 
GAGTCAACGGATTTGGTCGT-3'; GAPDH-R 5'- TTGATTTTGGAGGGATCTCG-3'; 
SatIII-F 5'-AATCAACCCGAGTGCAATCGAATGGAATCG-3'; SatIII-R 5'-
TCCATTCCATTCCTGTACTCGG-3' 3. 
For ChIP analysis, we used the following primer pairs: Satα-F 5'-
TAGACAGAAGCATTCTCAGAAACT-3'; Satα-R 5'-TCCCGCTTCCAACGAAA 
TCCTCCAAAC-3' 4; SatIII : same primer pair as for RT-PCR. 
 
 4 
Supplementary References 
1. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens 
M, Rubelj I, Pereira-Smith O. A biomarker that identifies senescent human cells in 
culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92:9363–9367. 
2. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect 
senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of 
senescent cells in culture and in vivo. Nature Protocols 2009; 4:1798–1806. 
3. Zhu Q, Pao GM, Huynh AM, Suh H, Tonnu N, Nederlof PM, Gage FH, Verma IM. 
BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 
2011; 477:179–184. 
4. Morozov VM, Gavrilova EV, Ogryzko VV, Ishov AM. Dualistic function of Daxx at 
centromeric and pericentromeric heterochromatin in normal and stress conditions. 
nucleus 2012; 3: 
5. Ray-Gallet D, Woolfe A, Vassias I, Pellentz C, Lacoste N, Puri A, Schultz DC, 
Pchelintsev NA, Adams PD, Jansen LET, Almouzni G. Dynamics of Histone H3 
Deposition In&nbsp;Vivo Reveal a Nucleosome Gap-Filling Mechanism for H3.3 to 
Maintain Chromatin Integrity. Molecular Cell 2011; 44:928–941. 
6. Shav-Tal Y, Blechman J, Darzacq X, Montagna C, Dye BT, Patton JG, Singer RH, 
Zipori D. Dynamic sorting of nuclear components into distinct nucleolar caps during 
transcriptional inhibition. Molecular Biology of the Cell 2005; 16:2395–2413. 
 
 5 
Supplementary Figures  
 
Figure S1: In vivo labeling assays for H3-SNAP-HAx3 in MRC5 human primary cells 
A. Scheme for the assays of in vivo labeling of H3-SNAP-HAx3 histones in Pulse, Quench-
Pulse and Quench-Chase-Pulse experiments in vivo. The Pulse labels pre-existing H3-SNAP 
with red fluorescent TMR-Star, the Quench-Pulse quenches pre-existing H3-SNAP with non- 
fluorescent Block preventing their subsequent labeling with TMR-Star and the Quench- 
Chase-Pulse labels new H3-SNAP synthesized during the 3h30 chase. HA labels total histone 
H3. Adapted from 5. 
B. Fluorescent microscopy visualization of total e-H3.1 and e-H3.3 (HA, green) 
colocalization with mitotic chromosomes in MRC5 cells. New H3.1 or H3.3 (TMR, red) were 
also labeled in vivo in a quench-chase-pulse experiment. During the chase period, new H3.3, 
but not H3.1, is incorporated in G2 phase cells which then subsequently entered into mitosis 
allowing detection of new H3.3 on mitotic chromosomes. DAPI stains nuclei. Scale bar is 10 
µm. 
C. Newly H3.1 is deposited during S-phase while H3.3 is deposited throughout the cell cycle. 
Fluorescent microscopy visualization of replication sites (BrdU, green) and of new H3.1 and 
H3.3 (TMR, red) after in vivo labeling in a quench-chase-pulse experiment. White and green 
arrowheads indicate typical negative and positive BrdU cells, respectively. DAPI stains 
nuclei. Scale bar is 10 µm. 
D. Histogram shows the percentage of H3.1 and H3.3 cells negative (BrdU –) or positive 
(BrdU +) for BrdU staining which are labeled with TMR-Star. Error bars indicate the standard 
deviation of two independent experiments (n=200 nuclei counted per experiment). 
 
Figure S2: New H3.3 is incorporated in oncogene-induced senescent MRC5 cells 
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A. Fluorescent microscopy visualization of proliferating (empty) or senescent (Ras) MRC5 
cells labeled with BrdU (green). We fixed cells at day 8 post-infection. DAPI stains nuclei 
and is a marker of SAHF formation. Scale bar is 10 µm. 
B. Conventional light microscopy vizualisation of a senescence associated Beta-Gal assay in 
MRC5 cells treated as in (A). Scale bar is 20µm.  
C. Histograms show quantitative analysis of senescence induction in MRC5 cells. BrdU 
positive cells are a marker of cell proliferation (left panel), while cells positive for SAHF 
(middle panel) or SA-β-Gal (right panel) are markers of senescence entry. Numbers represent 
the mean of 2-3 independent experiments ± s.d. 
D. Fluorescent microscopy visualization of new H3.1 and H3.3 (TMR, red) after in vivo 
labelling of MRC5 e-H3.1 and e-H3.3, transduced with an empty retroviral vector (empty) or 
with a vector expressing H-RasV12 (Ras) for 10 days, in a quench-chase-pulse experiment. 
Prior to fixation, soluble proteins were pre-extracted by detergent treatment (Triton) allowing 
detection of the incorporated histones only. HA (green) stains total H3 histones and DAPI 
stains nuclei. Of note, SAHF appear more fuzzy upon pre-extraction but H3.3 exclusion from 
SAHF is clearer. Scale bar is 10 µm. 
 
Figure S3: H3.3 does not accumulate in SAHF in oncogene-induced senescent cells. 
A. Quantitative RT-PCR analysis of H3.1, H3.3A and H3.3B mRNA levels in proliferating 
(empty) and senescent (Ras) MRC5 cells. We normalized levels to the reference gene 
GAPDH and set levels in proliferating cells to 100%. Error bars represent s.d. from 2 
independent experiments. 
B. Western blot analysis of fractionated cell extracts from MRC5 e-H3.1/e-H3.3, either 
proliferating (empty) or induced into senescence (Ras) for 9 days. 15µg of cytosolic (Cyt.) 
and nuclear salt-extractable (Nuc.) protein extracts and 25 µg of the chromatin pellet (Pellet) 
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were loaded. Mcm7 was used as a marker for cell proliferation and p16 as a marker for 
proliferation arrest. Membranes were probed for ATRX, DAXX, HIRA, ASF1a, H3.3 and 
Ras. Smc-1 and α-Tubulin served as loading controls. M: molecular weight marker.  
C. Fluorescent confocal microscopy visualization of new H3.3 (TMR) after in vivo labeling 
of MRC5 e-H3.3 cells proliferating (empty) or induced into senescence with H-RasV12 
overexpression (Ras) for 9 days in a quench-chase-pulse experiment. H3K9me3 and DAPI 
were used as markers for SAHF formation. Scale bar is 10 µm. 
D. Fluorescent microscopy visualization of endogenous H3.3 (green) in IMR90 ER:Ras cells, 
non-induced (no 4-OHT) or induced into senescence with 4-OHT (+ 4-OHT) for 6 days. 
DAPI stains nuclei. Insets representing enlarged images (3X) of selected area underscore 
absence of H3.3 accumulation in SAHF. Scale bar is 10 µm. 
 
Figure S4: H3.3 and its associated histone chaperones localize together in PML-NBs in 
proliferating and senescent cells  
A. Fluorescent microscopy visualization of endogenous H3.3 (green) in IMR90 ER:Ras cells, 
non-induced (no 4-OHT) or induced into senescence with 4-OHT (+ 4-OHT) for 6 days. One 
day prior to addition of 4-OHT, cells were transfected with control siRNA (siLuc) or siRNAs 
targeting H3.3A and H3.3B (siH3.3). siRNA transfection was performed a second time after 3 
days of 4-OHT. Absence of H3.3 staining in siH3.3 shows specificity of the antibody. PML 
(red) stains PML-NBs and DAPI stains nuclei. Insets representing enlarged images (3X) of 
selected area underscore localization of endogenous H3.3 in PML-NBs. Scale bar is 10 µm. 
B. Fluorescent microscopy visualization of new H3.3 (TMR, red) after in vivo labeling of 
MRC5 e-H3.3 cells either proliferating (empty) or induced into senescence (Ras) in a quench-
chase-pulse experiment. Co-staining with ASF1a (green) and HIRA (cyan, pseudo-color) 
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shows colocalization of new H3.3 with its chaperone ASF1a and HIRA in PML-NBs (white 
arrowheads). DAPI stains nuclei. Scale bar is 10 µm.  
C. Fluorescent microscopy visualization showing colocalization of histone H3.3 chaperones 
ATRX, DAXX, ASF1a or HIRA (red) together with PML (green) in normal MRC5 cells, 
proliferating (empty) or induced into senescence (Ras) for 12 days. Numbers indicate the 
mean percentage of cells with colocalization of the histone H3.3 chaperone within PML-NBs 
± s.d. from 2 independent experiments. DAPI stains nuclei. Scale bar is 10 µm.  
 
Figure S5: DAXX-dependent localization of ATRX at PML-NBs 
A. Western blot analysis of total cell extracts from MRC5 treated for 48h with the indicated 
siRNAs. Membranes were probed for ATRX, DAXX, HIRA (left panel) and H3.3 (right 
panel). α-Tubulin and Smc-1 served as loading controls. M: molecular weight marker. 
B. Fluorescent microscopy visualization of ATRX (red, left panel) or DAXX (red, right 
panel) in MRC5 cells treated as in (A) showing loss of ATRX from PML-NBs (green) upon 
DAXX depletion. Insets represent enlarged images of selected area. DAPI stains nuclei. Scale 
bar is 10 µm.  
 
Figure S6: ATRX localization to SAHF is increased in absence of DAXX  
A. Fluorescent microscopy visualization of ATRX (green) in MRC5 e-H3.3 cells treated as in 
Fig. 4A. Western blot analysis is shown in Fig. 4B. DAPI stains nuclei and is a marker of 
SAHF. Scale bar is 10 µm.  
B. Graphics show fluorescent intensity profiles quantified using Image J along lines drawn 
through nuclei as shown in panel (A). Comparison of profiles in proliferating (empty) cells 
treated with siLuc (i) or siDAXX1 (ii) shows loss of ATRX localization at PML-NBs upon 
DAXX depletion (see also Fig. S5B). In oncogene-induced senescent cells (Ras), ATRX 
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localization at PML-NBs increases (compare (iii) with (i)). Upon DAXX knockdown, ATRX 
localization to SAHF is increased (iv), since it is no longer targeted to PML-NBs. 
 
Figure S7: H3.3 localization to PML-NBs in absence of PML or HIRA 
A. Western blot analysis of total cell extracts from MRC5 e-H3.3 cells either proliferating 
(empty) or induced into senescence by H-RasV12 overexpression (Ras) for 7 days and treated 
with the indicated siRNAs during the last 48h. Membranes were probed for PML and Ras. 
Smc1 served as a loading control. M: molecular weight marker. 
B. Fluorescent microscopy visualization of new H3.3 (TMR, red) after in vivo labeling of 
proliferating MRC5 e-H3.3 cells treated as in (A) in a quench-chase-pulse experiment. New 
H3.3 localization at PML-NBs is lost in absence of PML (green). Insets represent enlarged 
images (3x) of selected area. DAPI stains nuclei. Scale bar is 10 µm.  
C. Histogram shows quantitative analysis of the proportion of cells showing new H3.3 
localization at PML-NBs. Numbers represent the mean of 2 independent experiments ± s.d. 
D. Western blot analysis of total cell extracts from MRC5 e-H3.3 cells treated as in (A). 
Membranes were probed for HIRA, Ras and HA. α-Tubulin served as a loading control. M: 
molecular weight marker. 
E. Fluorescent microscopy visualization of new H3.3 (TMR, red) after in vivo labeling of 
MRC5 e-H3.3 cells treated as in (A) in a quench-chase-pulse experiment. New H3.3 
localization at PML-NBs is not impaired in absence of HIRA. Insets represent enlarged 
images of selected area. DAPI stains nuclei. Scale bar is 10 µm.  
F. Histogram shows quantitative analysis of the proportion of cells showing new H3.3 
localization at PML-NBs. Numbers represent the mean of 2 independent experiments ± s.d. 
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Figure S8: Depletion of DAXX or ATRX or overexpression of DAXX in MRC5 cells 
does not impair senescence entry upon overexpression of H-RasV12  
A. Fluorescent microscopy visualization of MRC5 cells cotransduced with a virus encoding 
HRas-V12 (Ras, green) and a virus encoding a control shRNA (pRetro empty) or a virus 
encoding a specific shRNA targeting DAXX (shDAXX1) or ATRX (shATRX1) for 8 days. 
DAPI stains nuclei and is a marker of SAHF. DAXX (left panel) or ATRX (right panel) are 
stained in red. Scale bar is 10 µm.  
B. Histogram shows quantification of the mean number of positive cells for SAHF formation 
for cells treated as in (A). Error bars represent s.d. from 2 independent experiments. 
C. Western blot analysis of total cell extracts from MRC5 treated as in (A). Membranes were 
probed for DAXX and Ras to verify expression of these proteins. Cyclin A was used as a 
marker for cell proliferation and p16 as a marker for proliferation arrest. α-Tubulin served as 
a loading control. The vertical bar indicates that a lane was cut from the gel. M: molecular 
weight marker. 
D. Western blot analysis of total cell extracts from MRC5 empty cells or MRC5 
overexpressing Myc-DAXX, transduced with an empty vector or with a vector expressing 
oncogenic Ras for 8 days. Membranes were probed for Myc, DAXX, and Ras to verify 
expression of the transduced proteins. Cyclin A was used as a marker for cell proliferation 
and p16 as a marker for proliferation arrest. α-Tubulin served as a loading control. M: 
molecular weight marker. 
E. Fluorescent microscopy visualization of MRC5 cells treated as in (D). Myc (red) stains the 
epitope-tagged Myc-DAXX. DAPI stains nuclei and is a marker of SAHF. Scale bar is 10 
µm. 
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Figure S9: Depletion of DAXX, ATRX or H3.3 in IMR90 ER:Ras does not impair 
senescence entry upon overexpression of H-RasV12 
A. Scheme for the assay of induction into senescence in IMR90 ER:Ras. Cells were first 
transduced with a virus encoding a control shRNA (empty) or a virus encoding an shRNA 
against DAXX (shDAXX1) or ATRX (shATRX1). 5 days later, IMR90 ER:Ras were induced 
into senescence by addition of 4-OHT (100nM) and senescence was assessed 6 days after. 
B. Immunofluorescence analysis of IMR90 ER:Ras treated as in (A). DAXX (red, left panel) 
or ATRX (red, right panel) proteins are depleted in the specific shRNAs. DAPI stains nuclei 
and is a marker of SAHF. Scale bar is 10 µm. 
C. Histogram shows quantification of the mean number of positive cells for SAHF formation 
for cells treated as in (A). Error bars represent s.d. from 2 independent experiments. 
D. Conventional light microscopy vizualisation of a senescence associated Beta-Gal assay in 
IMR90 ER:Ras cells treated as in (A). Scale bar is 20µm. 
E. Western blot analysis of total cell extracts from IMR90 ER:Ras cells treated as in (A). In 
addition, IMR90 ER:Ras transduced with an empty virus (pLNCX2 empty) or a virus 
encoding Myc-DAXX (Myc-DAXX) were also included in the analysis of senescence 
induction with 4-OHT for 6 days. Membranes were probed for Myc, DAXX, and Ras to 
verify expression of the transduced proteins. Cyclin A was used as a marker for cell 
proliferation and p16 as a marker for proliferation arrest. α-Tubulin served as a loading 
control. M: molecular weight marker. The vertical bar indicates that a lane was cut from the 
gel. As shown on MRC5 cells in Fig. S8, depletion or overexpression of DAXX does not 
impair senescence entry. 
F. Western blot analysis of total cell extracts from IMR90 ER:Ras cells, non-induced (no 4-
OHT) or induced into senescence with 4-OHT (+ 4-OHT) for 6 days. One day prior to 
addition of 4-OHT, cells were transfected with control siRNA (siLuc) or siRNAs targeting 
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DAXX (siDAXX1 or siDAXX3), ATRX (siATRX1) or H3.3A and H3.3B (siH3.3). siRNA 
transfection was performed a second time after 3 days of 4-OHT. Membranes were probed for 
ATRX, DAXX, H3.3 and Ras to verify expression of these proteins. Cyclin A was used as a 
marker for cell proliferation and p16 as a marker for proliferation arrest. α-Tubulin served as 
a loading control. M: molecular weight marker.  
G. Histogram shows quantification of the mean number of positive cells for SAHF formation 
for cells treated as in (F). Error bars represent s.d. from 2 independent experiments. 
H. Fluorescent microscopy visualization of IMR90 ER:Ras cells treated as in (F). Addition of 
4-OHT (+4-OHT) triggers accumulation of HRas-V12 (green) and senescence induction. 
DAPI stains nuclei and is a marker of SAHF. DAXX or ATRX are stained in red. Arrowheads 
indicate ATRX localization at SAHF. Scale bar is 10 µm. See also Fig. S4A for 
immunofluorescence analysis of siH3.3 treated cells.  
 
Figure S10: Overexpression of DAXX triggers accumulation of new H3.3 in PML-NBs 
A. (Left panel) Fluorescent microscopy visualization of new H3.3 (TMR, red) after in vivo 
labelling of MRC5 e-H3.3 cells transduced with an empty vector (Empty) or a vector 
expressing Myc-DAXX (Myc-DAXX) and co-stained with Myc (green) and DAXX (cyan, 
pseudo-color). Scale bar is 10 µm. (Right panel) Graphics show distribution of new H3.3 
(TMR) signal in MRC5 e-H3.3. TMR fluorescence intensity of each pixel delimited within 
the nuclei is plotted in a 3D-surface plot shows increase of targeting of H3.3 at PML-NBs 
upon DAXX overexpression.  
 B. Fluorescent microscopy visualization of new H3.3 (TMR, red) after in vivo labelling of 
proliferating (empty) or senescent (Ras) MRC5 e-H3.3 cells in a quench-chase-pulse 
experiment. Prior to fixation, soluble proteins were pre-extracted by detergent treatment 
(Triton) allowing detection of the triton-insoluble proteins only. Co-staining with H3K9me3 
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(green) and PML (cyan, pseudo-color) shows colocalization of new triton-insoluble H3.3 
within the PML-NBs and exclusion from SAHF, marked as H3K9me3 dense regions. Scale 
bar is 10 µm.  
 
Figure S11: New H3.3 localizes in PML-NBs in nucleolar caps upon transcription 
inhibition. 
A. Fluorescent microscopy visualization of new H3.3 (TMR, red) after in vivo labelling of 
MRC5 e-H3.3 in a quench-chase-pulse experiment. Cells were treated with DMSO or with 
Actinomycin D (ActD) at a dose of 2µg/mL for the total lenght of the chase (3h30) to prevent 
transcription of new H3.3 (control, no TMR signal), or for the end of the chase (1h30) to 
allow synthesis of new H3.3 before transcription inhibition. In this latter case, new H3.3 
relocalizes together with PML in nucleolar caps as shown previously for PML upon 
transcription inhibition 6. Insets represent enlarged images (3X) of selected area. PML (green) 
stains PML-NBs and DAPI stains nuclei. Scale bar is 10 µm.  
B. Fluorescent microscopy visualization of new H3.3 (TMR, red) as in A. MRC5 e-H3.3 were 
transduced with an empty retroviral vector (empty) or with a vector expressing H-RasV12 
(Ras) for 7 days. Actinomycin D (ActD) at a dose of 2µg/mL was added during the end of the 
chase (1h30). Insets represent enlarged images (3X) of selected area. PML (green) stains 
PML-NBs and DAPI stains nuclei. Scale bar is 10 µm. 
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Supplementary Table SI: List of primary antibodies 
Antibody Company/Reference Order number Lot number Species WB dilution IF dilution 
ASF1a Mello et al., 2002 #28134 - Rabbit polyclonal 1/1000 1/1000 
α-Tubulin SIGMA T6199 - Mouse monoclonal 1/200 - 
ATRX Santa Cruz Biotechnology 
sc-15408 (clone 
H-300) F0211 
Rabbit 
polyclonal 1/1000 1/250 
Cyclin A Santa Cruz Biotechnology 
sc-751 (clone H-
432) G0811 
Rabbit 
polyclonal 1/1000 - 
DAXX Santa Cruz Biotechnology 
sc-7152 (clone M-
112) E1412 
Rabbit 
polyclonal 1/1000 1/250 
HA Abcam ab9110 - Rabbit polyclonal 1/6000 1/1000 
HIRA Active Motif 39558 (clone WC119.2H11) 909001 
Mouse 
monoclonal 1/1000 1/100 
HP1γ  Pierce - Thermo Scientific PA5-17445 OB1666806 
Rabbit 
polyclonal - 1/200 
H3.3 Abnova H00003021-M01 (clone 2D7-H1) 12264-S1 
Mouse 
monoclonal 1/100 1/100 
MCM7 Santa Cruz Biotechnology 
sc-65469 (clone 
DCS-141) H0210 
Mouse 
monoclonal 1/500 - 
Myc GeneTex GTX80249 - Mouse monoclonal 1/2000 1/250 
PML Santa Cruz Biotechnology 
sc-5621 (clone H-
238) K2912 
Rabbit 
polyclonal 1/500 1/100 
PML Santa Cruz Biotechnology 
sc-966 (clone PG-
M3) F1511 
Mouse 
monoclonal - 1/250 
p16 Santa Cruz Biotechnology 
sc-56330 (clone 
JC8) I2512 
Mouse 
monoclonal 1/200 - 
Ras BD Transduction Laboratories 610001 82593 
Mouse 
monoclonal 1/1000 1/500 
Smc1 Abcam ab9262 GR1468-4 Rabbit polyclonal 1/1000 - 
IgG Santa Cruz Biotechnology sc-2027 C0411 
Rabbit 
Polyclonal 1µg for IP - 
